Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5ISZ1
|
|||
| Drug Name |
NKTR-214
|
|||
| Synonyms |
bempegaldesleukin
Click to Show/Hide
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 3 | [1] | |
| Company |
Nektar Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 2 receptor beta (IL2RB) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Measles | ||||
| HTLV-I infection | ||||
| Transcriptional misregulation in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| SHP2 signaling | ||||
| IL2-mediated signaling events | ||||
| IL2 signaling events mediated by PI3K | ||||
| IL2 signaling events mediated by STAT5 | ||||
| Downstream signaling in naï | ||||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-2 signaling | ||||
| RAF/MAP kinase cascade | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | IL-2 Signaling Pathway | |||
| Inflammatory Response Pathway | ||||
| Interleukin-2 signaling | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.